Divergent ERα Co-factor Landscapes in Gynecological Cancers: Implications for Disease Progression and Therapy
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Estrogen receptor alpha (ERα) is key in breast cancer treatment. Paradoxically, ovarian and uterine cancers expressing ERα are often therapy-resistant, suggesting cofactor differences influence treatment response.
Area Of Science
- Oncology
- Molecular Biology
- Genomics
Background
- Estrogen receptor alpha (ERα) is a vital biomarker in breast tumors, with its expression linked to cancer progression.
- Targeting ERα has proven effective in managing breast cancer, yet a significant portion of ovarian and uterine cancers expressing ERα remain insensitive to antiestrogenic therapies.
Purpose Of The Study
- To investigate the hypothesis that ERα's association with cofactors influences cancer susceptibility to antiestrogenic therapies.
- To explore differences in ERα cofactor interactions and genomic localization across breast, ovarian, and uterine cancers.
Main Methods
- Analysis of patient sample data from cBioportal to assess correlations between ERα and cofactors (GATA3, FOXA1).
- Examination of available ChIP-seq datasets to determine ERα genomic localization patterns in different cancer types.
Main Results
- A strong positive correlation between ERα and cofactors GATA3 and FOXA1 was observed in breast cancer, but not in ovarian and uterine cancers.
- Significant differences in ERα genomic localization were identified among breast, ovarian, and uterine cancers.
Conclusions
- ERα cofactor association and genomic localization patterns may dictate the efficacy of antiestrogenic therapies in different gynecological cancers.
- These findings suggest distinct mechanisms driving ERα-dependent cancer progression in various cellular contexts, highlighting potential therapeutic avenues.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...